Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Jul 16, 2024
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kymera Therapeutics, Inc.
|
0
|
$23.90 | -$1,720,774.99 |
—
| 201.07K |
Jul 15 - Jul 16
| |||||||
Kymera Therapeutics, Inc.
| 21.03K |
$41.86 | -$139,967.47 | +28.15% | 95.74K |
Mar 1 - Mar 4
| |||||||
Kymera Therapeutics, Inc.
|
0
|
$23.54 | -$17,168.00 |
—
| 74.71K |
Feb 27
| |||||||
Kymera Therapeutics, Inc.
|
0
|
$18.79 | -$1,542,106.53 |
—
| 74.71K |
Feb 9
| |||||||
Kymera Therapeutics, Inc.
| 17.45K |
$31.00 | -$40,233.28 | +30.48% | 74.71K |
Mar 1 - Mar 2
|
Scheduled
| ||||||
Kymera Therapeutics, Inc.
| 20K |
$1.69 | $33,739.84 | +53.68% | 57.26K |
May 4
| |||||||
Kymera Therapeutics, Inc.
| 12.6K |
—
|
—
| +51.10% | 37.26K |
Mar 1
| |||||||
Kymera Therapeutics, Inc.
| -17.89K |
$31.92 | -$3,506,683.67 | -42.05% | 24.66K |
Nov 1 - Nov 2
|
Scheduled
| ||||||
Kymera Therapeutics, Inc.
| -5.00K |
$30.72 | -$888,890.83 | -10.52% | 42.55K |
Mar 11 - Mar 15
|
Scheduled
| ||||||
Kymera Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Mar 1
| |||||||
Kymera Therapeutics, Inc.
| -37.06K |
$50.68 | -$1,878,355.25 | -43.81% | 47.55K |
Feb 22 - Feb 24
|
Scheduled
| ||||||
Kymera Therapeutics, Inc.
| -22.94K |
$56.42 | -$1,293,935.66 | -21.33% | 84.61K |
Feb 17 - Feb 19
|
Scheduled
| ||||||
Kymera Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Aug 20
| |||||||
Kymera Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. | |||||||||||||